Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Aug 13:16:741-747.
doi: 10.2147/TCRM.S246328. eCollection 2020.

Comparison of Adverse Event Profiles of Tumor Necrosis Factor-Alfa Inhibitors: Analysis of a Spontaneous Reporting Database

Tomohito Wakabayashi  1 , Keiko Hosohata  1 , Saki Oyama  1 , Ayaka Inada  1 , Sayaka Ueno  1 , Hiroko Kambara  1 , Tatsuya Iida  1 , Takahiro Nakatsuji  1 , Mayako Uchida  1 , Kazunori Iwanaga  1
Affiliations

Comparison of Adverse Event Profiles of Tumor Necrosis Factor-Alfa Inhibitors: Analysis of a Spontaneous Reporting Database

Tomohito Wakabayashi et al. Ther Clin Risk Manag. .

Abstract

Introduction: Concerns over safety profiles of tumor necrosis factor (TNF)-alfa inhibitors have been raised. The purpose of this study was to clarify the adverse events associated with TNF-alfa inhibitors using a spontaneous reporting system database.

Materials and methods: A retrospective pharmacovigilance disproportionality analysis was conducted using the Japanese Adverse Drug Event Report (JADER) database. Adverse event reports submitted to the Pharmaceuticals and Medical Devices Agency between 2004 and 2017 were analyzed, and the reporting odds ratio (ROR) and 95% confidence interval (CI) for each adverse event were calculated.

Results: Among the 34,031 reports of adverse events associated with TNF-alfa inhibitors, 65.8% were women, who were frequently in their 60s (28.2%). Signals were detected for pneumonia (ROR, 5.36; 95% CI, 5.14-5.6), interstitial lung disease (ROR, 2.04; 95% CI, 1.95-2.15), pneumocystis jirovecii pneumonia (ROR, 11.8; 95% CI, 11.1-12.5), and herpes zoster (ROR, 6.4; 95% CI, 5.92-6.91) for TNF-alfa inhibitors as a class. There was variability in their signal strength across individual TNF-alfa inhibitors.

Conclusion: The strength of the associations of TNF-alfa inhibitors with adverse events is variable, and further studies are required to evaluate the identified signals.

Keywords: Japanese Adverse Drug Event Report database; TNF-alfa inhibitors; adverse drug events; reporting odds ratio; spontaneous reporting system.

PubMed Disclaimer

Conflict of interest statement

The authors report no conflicts of interest in this work.

References

    1. Ettehadi P, Greaves MW, Wallach D, Aderka D, Camp RD. Elevated tumour necrosis factor-alpha (tnf-alpha) biological activity in psoriatic skin lesions. Clin Exp Immunol. 1994;96:146–151. doi:10.1111/j.1365-2249.1994.tb06244.x - DOI - PMC - PubMed
    1. Sandborn WJ, Hanauer SB, Rutgeerts P, et al. Adalimumab for maintenance treatment of crohn’s disease: results of the classic ii trial. Gut. 2007;56:1232–1239. doi:10.1136/gut.2006.106781 - DOI - PMC - PubMed
    1. van de Kerkhof PC, Griffiths CE, Reich K, et al. Secukinumab long-term safety experience: A pooled analysis of 10 Phase II and iii clinical studies in patients with moderate to severe plaque psoriasis. J Am Acad Dermatol. 2016;75(83–98):e84. doi:10.1016/j.jaad.2016.03.024 - DOI - PubMed
    1. Smolen JS, Kay J, Doyle MK, et al. Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (go-after study): A multicentre, randomised, double-blind, placebo-controlled, phase iii trial. Lancet. 2009;374:210–221. doi:10.1016/S0140-6736(09)60506-7 - DOI - PubMed
    1. Mahe J, de Campaigno EP, Chene AL, Montastruc JL, Despas F, Jolliet P. Pleural adverse drugs reactions and protein kinase inhibitors: identification of suspicious targets by disproportionality analysis from vigibase. Br J Clin Pharmacol. 2018. doi:10.1111/bcp.13693 - DOI - PMC - PubMed